SLC5A2 and type 2 diabetes mellitus: Importantly, the first recognition of SGLT2 inhibition benefits beyond diabetes control was by the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).